Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant ...

The anti-amyloid therapy gantenerumab lowered the chances for developing Alzheimer’s-related dementia in people at high risk for the disease, according to a small study conducted by the Knight Family ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...